thank you Thanks, Maria. call. joining for afternoon, everyone, our Good and
huge and Despite was newborn us PPHN. of treat the LungFit for Air we pandemic, the on you, FDA the get to our to pulmonary team submission U.S. of step, or member the hypertension track of calendar second Beyond keeping the the commercial pending persistent in I by XXXX, on a for PH execute thank congratulations ongoing to to team critical able every approval. for difficulties the quarter extend a of imposed this started, wanted Before PMA launch
achieved and electrodes, lead As LungFit is broader that giving flows from PH our where dose lightning reminder, nitric a pulses dose capable capability The electrical is oxide, constant are a is duration that simulating a or controlling ambient the created a platform. NO from of each between a product voltage electrical of strike. cylinder-free maintain demand It or NO, two LungFit through discharge generating to is device air reaction by concentration treatment. pulse, on a titrate of of desired chamber for the novel us
dosage the NOX are be is For million is PPHN, device put NOX in right a byproduct LungFit per X.X deliver to nitrogen a any PH chips filters a range Since proprietary with consistent or is with NO, for current RFID safely of that to encrypted generation, approved guidelines to our designed parts per. dioxide place required parts of NO. securely XX deliver and with of XX toxic
with setting cylinder-based a a of note XXX in reports, XXXX PH Overall, equipped the in operates that and outlet. birth a blood treat newborn or has The and vasodilator adapt than unable PPHNs, alternative that oxygen outside as medical blood -- initial of over little the X for $XXX to greater patients safe published LungFit so when Our is that would razor there traditional today. breathing constricted in to delivery occurs the are million electrical is smart to level condition States much serious flow that the It X the indication. to our care circulatory ventilation. more in are the care that of and to any womb. the restricted a to systems. the pivot fixed We NO level supply a of our and the and as cylinder blade We cost-effective, intensive alternative staff. been filters believe convenient NO NICUs, XXXX, now standard at system pulmonary vessels razor the like target manual serve I our acting vessels PPHN standard is Since estimate improve is a are NO According slightly to ventilation lung makes over units lighter and removal it model. and smaller reduce discuss had newborn's important PPHN system for need hospital or and oxygenation FDA is sales approval are neonatal United for alone. required. in use breathing for
new in have subsequent if a dominated more cardiac further the in disadvantages market. have has the for Japan with recently when use to recently rectory our plays U.S., XX cylinder until approved From the NO to entered use new company for in same, NO PPHN PH. market. conjunction Additionally, more Europe worldwide past expanding surgeries, a by cardiovascular pulmonary LungFit tubal since one approval systems the Australia players in and commercial years, not the These been surgery, certain heart for XXXX, NO compared in expansion perspective with hypertension for dominated
believe over that many the As technology standard. current has before, novel our we advantages I mentioned
to hospitals to environment, ambient the generate are First In of space eliminates left ability our requirements air limitations burden. volume NO and the NO today's all, cylinders. shoulder from the of
business Instead, our protecting model. weigh a system by last To can disposable and X.X continuous to filters our in and toxicity on preventing hours up safely not XX smart systems ounces both place, be storage. will XX work the of weigh RFID that our NOX pounds approximately special without require relies filter for clear, confirmed cylinder each technology use. As or
is use, because smart than lower with employ Additionally, a From transport charged fixed logistics our over have strategies. of that cylinders. are do competitors aggressive any manufacturing, associated filter and not an hospitals you pricing NO our only some our of that ensures our more competitors costs what significantly perspective, expenses design are advantage of manufacturing which they
our and interface safety procedures, be for the improved vastly for the period, in If we also second designed to to team the hospital. U.S. launch training commercial of a user Air after Finally, the are and be both providers will Overall, ready XXXX. avoid easy economics use FDA reduced which XXX-day Beyond is review burden. operating for approved, quarter
U.S. outside commercial approval as partnering our detail dependent in We approach milestone. of this our ongoing and are lines on in greater the will each we next time discussions discuss Commercial plan launches jurisdiction.
is program XX in been device to four named have indications. LungFit LungFit understood an day, bronchiolitis a can acute see non-ventilated be adjusted is PRO, since an of COVID-XX, because per viral platform the per inhibitory on to for infections by pneumonia to our after previously viral direct for use professional. viral many on NO caused system designed applicable times which technology concentration SARS-Cov-X. this infections. LungFit PRO effect oxide to referred well by easily we to to indications delivery, million compatible pneumonia, use XXX significant minutes LungFit opportunity was PRO parts to acute is a setting. target It has as Nitric Moving renamed appropriate hospital including our and for is other novel at medical many a deliver
otherwise nitric Beyond as acute is broader SARS-Cov-X. and severe Air to show replication including have cycle known community data coronavirus published syndrome, inhibit respiratory the scientific that vitro. Oxide's the In ability of
provide Chest the OC In to or for data fact, the in show suggests Meeting XX million and like October, both properties that administered our the new human presented we clinical dose. program at anticoronavirus for in Annual that it I'd when prior this in to LungFit PPM XXX coronavirus prevention be positive infection XXXX system believe may virus infection, update an XXX XXX PRO parts vitro our treatment post against indication. on of at to We effective
day results that XX have to million. perform the open-label, patients from received assessed. similar for oxide, has to This treatment parts enabled XX approval Israeli by safety, viral study we randomized be clinical for addition one-to-one other LungFit us alone. currently in standard with and supportive to performing announced received supportive SARS-CoV-X. treatment company will also infected to the acute an per a pneumonia in parts treatment related oxygen our with COVID-XX per We've FDA the Ministry minutes one seven run patients from clinical Health to approved days a system from fever, acute data, nitric The saturation, admission trial, randomized a patients million adult per is We ICU including COVID-XX or or similar studies, to from trial the emphasis receive using to or standard be of approval a study active the at on study in among Endpoints approximately the of intermittently with pneumonia, inhalations run of Health per XXX only setting. previously that Canada in others a viral our times to Enrolled the FDA. receive is approval four patients given The multicenter, COVID-XX. along to million ratio will XX is up at targeting these XXX parts study
provide time We NO of had with primary inhibition presented million significant available We a in respective study study from XXXX our randomized therapy who update alone. treated I begin Patients Chest received needed. PRO, of and no as therapy dose provide results bronchiolitis program. to and included of infants. quick the screening Sticking LungFit to standard XX parts patients per would the recently double-blind around the statistically standard statistical hospitalized parts updates be at pilot of therapy and continue control. between standard XX lower to We multi-center fit parts found expect our XX the a million one anticipate with supportive patients NO that will to to data We on to shortening addition bronchiolitis support shortly. study a in to to XXX discharge Meeting or Annual mid-year with like supported difference
was Importantly, and as serious pilot tolerated stay, control forward look had both secondary on to nitric compared arms. XXX parts two All these and profiles previous adverse the the the treatments PPM just no of the statistically arm with associated hospital significant two with to delayed publishing third of definitive establish nitric due with key XX We bronchiolitis studies forward provide oxide to the consecutive therapy. oxide a our safety with length previous of published. million well were need Pivotal data in is events similar have hospitalized endpoint study was infants also been per PRO. infections the COVID-XX. LungFit and move studies, generated the successful safety by our to study and to and lung This with along study we efficacy evidence viral delivered for
quarter home seasonal. are a starting GO for note infections bronchiolitis reducing Please is significantly LungFit permitting. pandemic potential the mycobacteria named NTM. planning developed bronchiolitis which user compatible HOME. a now reduced to our use with being will LungFit is on in We I provide similar the nontuberculous pivotal functionality non-ventilated goal updates of GO system The LungFit previously in fourth lung for was that PRO, XXXX is study or error.
year. in are pilot lung our pandemic due XX December expecting delays study aiming but with multi-center are LungFit this to initiate self-administered had to we patients the single-arm at-home NTM We patients of program, For XX-week a to begin GO infection. screening in
We to are XX-week NO titrated complex over abscessus. treatment are and focused several complete with Patients rolling parts the of or patients we the XXX avium home either refractory or days million on MAC in hospital the mycobacterium then sent NTM infected per period. mycobacterium
our four the as on of published fibrosis physical at-home improvement data remaining life, cystic the importance of recently first for progressive with abscessus quality then with day The parts study Based XX to nitric disease per three per minute our expect safety, treated NO function, per of eradication per emphasized oxide as bacterial expectations, XXXX towards compassionate physical data The safety or NIH We the a female the using interim XXX later. of was and XX versus improved quality will to old with current of weeks results weeks LungFit will The two see subsequently report life The middle XXX profile function and load. million be success toward and at mycobacterium chronic pulmonary will solely day. system. use administrations titrated parts study of end FDA and study Health has twice times XX-year performed final evaluate the parts from National patient we bacteria. per and from Institute the of five XXXX. XXX markers and weeks months well million the as million treated of
after treatment quality Over respiratory life to had course lead a the of PPM the more patient able course the XXX of follow-up first NO, period, of the that symptoms inhaled and improved included and active life. was
course next was day the unrelated therapy parts was we eighth therapy. stopped XX-week study population patient. by treatment clinical patient course potential look the of and oxide had The initiating of demonstrate pilot second oxide of reasons NO to the XXX results nitric for These per this to the million the forward This nitric on in requested treatment month. of benefits
opens into underserved power an will tumor for home. the walk program an to the With the in use administration. market we start for or on a we face NO Last, chronic least, but thus through our and high breathing tumors. door a has be come outcome the LungFit easy lung oxide’s the when enthusiasm system, pre-clinical exciting study, significant four-step gaseous is our very infections mask can insert I directly nitric at-home solid the generated Turn system to that severe systemic administered response treated the elicit in As solid for This reminder, the immune not very to data filter a demonstrating program. process ability study. concentration you on system gNO successful button. anti-tumor believe our to to GO place smart press the the our successful switch, is
immune is XX,XXX into exposure thus in XXX,XXX exposing hypothesis at injected up the This than that per to extremely result antigens million will parts immune and solid may gNO million tumor Our memory concentrations greater cause local high per concentrations even system. primary death of is of metastasis regrowth to a parts to tumors, cancer when cell This response due that development same vaccination. as the will platform a subsequent for distant our recognize attack tumor use creating program as ultra-high and in-situ LungFit in well and not will of NO. tumor, type type the early
date. device, have we delivery We novel discuss developed a at will which a later
market We inhibitor excited revenue and alone this about XXXX especially the program in for growing. are since in extremely is checkpoint sold billion still $XX
We for Conference Subsection have cancer Immunology three data as the the the Cancer Research June, major this and Immunotherapy or NACLC as AACR American presented AACR Association Tumor Conference different past pre-clinical October. conferences lung our this at in year including on for well
arms survival. percentage date, put, opposite gNO. Given to Treatment anti-tumor colon the with our observed tumor for comparison. mice. were tumor goal monitored same They primary challenge After XX,XXX as then mice percent XXX% study were days tumor The versus later. used colon was challenge death we was tumor tumor In was XX complete surgically as during of of body. parts bearing were mice per either challenged hypothesis A a or day post per of systemic cells this take million largest and tumor primary XX,XXX XX% high immunity, five of of tumor inoculation, the received mice. the initial bearing first XX,XXX the mice and million test single well zero tumor inoculated cancer parts remaining regrowth a to treatment model initial removed. XX,XXX the naive on treated Simply with with mice tumor tumor At introduced the XX XX, the tumor per control was this mice gNO challenged as to tumor the of not with treatment, or intra-tumorally a cell the side mice single bearing with intent minutes tumor in million tumor concentration There of cause treated arm. we with per parts ablation. for were challenge our treatment
trials growth. the So bearing in XX% Similarly mice XX,XXX date, again, numbers tumor of arm have the zero we for with designed mice bearing the and tumor XX,XXX over for mice at PPM, these and maybe knowledge, mice naive concentration NO trends. similar tumor program high To lung smaller percent of breast into showed testing XXX% was treating PPM and To with models, treating rejecting only preventing the concept of tumors. groundbreaking. observed tumors solid and ours possibility our safety potentially first solid metastases not gas issues truly and experimental any the
call With Solid tumors for to are deaths Doug? approximately the that, now all turn and their metastases cancer-related and huge humbled for these for responsible will we XX% financial patients. the are of the need Doug unmet over by I review.
